Biomerica's InFoods Irritable Bowel Syndrome Diagnostic-Guided Therapy Clinical Trial Nears Completion of Enrollment - Seite 2

Biomerica will commence the final pivotal trial following the completion of the clinical endpoint trial.

About IBS
It is estimated that over 45 million Americans suffer from IBS.¹ IBS is a common condition that can significantly impair the physical and mental well-being and a person's ability to function at home and in the workplace. The symptoms of IBS are often triggered by the consumption of specific foods, which differ for every individual. The total cost of IBS has been estimated at $30 billion annually in just the United States.

About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global, biomedical technology company that develops, patents, manufactures, and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and physicians' offices) and in hospital/clinical laboratories, for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases, where the Company has multiple diagnostic and therapeutic products in development.

About InFoods
The Biomerica InFoods IBS product is designed to allow physicians to identify patient-specific foods (e.g. eggs, broccoli, wheat, potatoes, corn, etc.), that when removed from the diet, may alleviate or improve an individual's IBS symptoms including, but not limited to, constipation, diarrhea, bloating, severe pain and indigestion. This patented, diagnostic-guided therapy is designed to allow for a patient-specific, guided dietary regimen to improve IBS outcomes. A point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample, while a clinical lab version of the product is expected to be the first for which the Company will seek regulatory approval. A billable CPT code that can be used by both clinical labs and physicians' offices is already available for InFoods diagnostic products. Since the InFoods product is a diagnostic-guided therapy, and not a drug, it has no drug type side effects. An estimated 45 million people in America currently suffer from IBS making it a leading cause for patient doctor visits.